Delivery Order SPE2DB24D2100-SPE2DB26FBAHQ
- Not listed
- The Defense Logistics Agency awarded a delivery order valued at $2,276.24 to AmerisourceBergen Drug Corp for Quillivant XR 25 mg/5 ml suspension (120 ml) on September 15, 2025, with an ultimate completion date of September 16, 2025. This competitively awarded, non-set-aside contract utilizes firm fixed pricing and represents a child delivery order under AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop Support Medical (SPE2DX), a $999,999,999.00 vehicle running through...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on July 21, 2025, for the supply of Quillivant XR 25 mg/5 ml suspension in 60 ml quantities, valued at $1,182.78. This firm fixed-price delivery order, with an ultimate completion date of July 22, 2025, represents a non-competitive set-aside award and will be performed at the contractor's corporate office location in Conshohocken, Pennsylvania. The contract is issued as a child order under AmerisourceBergen's...
- The Defense Logistics Agency's Medical Supply Chain awarded a delivery order valued at $5,357.13 to AmerisourceBergen Drug Corp for Quillivant XR oral suspension (150mL, 5mg/mL) on August 11, 2025, with completion scheduled for August 12, 2025. This firm fixed-price delivery order was competitively awarded without set-aside restrictions and will be performed at the contractor's facility in Conshohocken, Pennsylvania. Quillivant XR is a long-acting formulation of methylphenidate used to treat...
- The Defense Logistics Agency awarded a delivery order valued at $3,509.82 to AmerisourceBergen Drug Corp for the supply of Quillivant XR 25 mg/5 ml suspension in 60 ml quantities. The contract was awarded on July 29, 2025, with an ultimate completion date of July 30, 2025, and represents a firm fixed price, competitively awarded delivery order with no set-aside designation. AmerisourceBergen Drug Corp, headquartered in Conshohocken, Pennsylvania, will perform the delivery from its corporate...
- The Defense Logistics Agency awarded a delivery order valued at $1,314.20 to AmerisourceBergen Drug Corp on June 2, 2025, for the supply of Quillivant XR 25 mg/5 ml suspension in a 180 ml quantity. This competitively awarded, firm fixed-price delivery order represents a non-set-aside procurement with an ultimate completion date of June 3, 2025, and will be performed at the contractor's corporate office location in Conshohocken, Pennsylvania. Quillivant XR is a long-acting formulation of...
- The Defense Logistics Agency awarded a delivery order valued at $1,898.96 to AmerisourceBergen Drug Corp for Quillivant XR 25 mg/5 mL Suspension (120 mL) on August 26, 2025, with an ultimate completion date of August 27, 2025. This firm fixed-price delivery order was competitively awarded without a set-aside designation and will be performed at AmerisourceBergen's facility in Conshohocken, Pennsylvania. Quillivant XR is a long-acting formulation of methylphenidate used to treat...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp, the prime contractor on a larger Indefinite Delivery Contract (IDC) valued at $999,999,999 through December 2026, to supply Quillivant XR 25 mg/5 ml suspension in a 150ml quantity. This firm fixed-price delivery order, valued at $1,577.04, was competitively awarded without a set-aside designation and is scheduled for completion by July 31, 2025. The product will be delivered to AmerisourceBergen's facility in...
- The Department of Defense's Medical Supply Chain awarded a delivery order to AmerisourceBergen Drug Corp on September 18, 2025, for the supply of Quillivant XR 25 mg/5 ml suspension in a 120 ml quantity. This is a firm fixed-price delivery order with a ceiling value of $3,253.59 and an ultimate completion date of September 19, 2025. The award represents a non-competitive delivery order issued under AmerisourceBergen's larger Indefinite Delivery Contract with the Defense Logistics Agency Troop...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on August 11, 2025, for the supply of Quillivant XR 25 mg/5 ml suspension (180 ml) with a ceiling value of $2,688.53. This is a firm fixed-price delivery order with no set-aside designation, issued competitively under the company's existing Indefinite Delivery Contract with DLA Troop Support Medical (SPE2DX). The product will be delivered to the company's facility in Conshohocken, Pennsylvania, with an...
- The Defense Logistics Agency (DLA) awarded a delivery order to AmerisourceBergen Drug Corp on April 23, 2025, for the supply of Quillivant XR 25 mg/5 ml suspension (180 ml) with a ceiling value of $4,169.79. This is a firm fixed price delivery order with no set-aside designation, competitively awarded under an Indefinite Delivery Contract (IDC) mechanism. The order is due for completion by April 24, 2025, and will be performed at AmerisourceBergen's headquarters location in Conshohocken,...
- SPE2DB24D2100Indefinite Delivery Contract
- SPE2DB24D2100-SPE2DB26FBAHQDelivery Order
The Defense Logistics Agency awarded a $11,339.81 delivery order to AmerisourceBergen Drug Corp for Quillivant XR 25 mg/5 ml suspension (180 ml) on October 17, 2025, with an ultimate completion date of October 20, 2025. This competitive, non-set-aside award utilizes firm fixed price pricing and represents a child order under AmerisourceBergen's larger indefinite delivery contract vehicle. The product will be performed at the awardee's facility in Conshohocken, Pennsylvania. Quillivant XR is an extended-release formulation of methylphenidate used to treat attention deficit hyperactivity disorder. This delivery order is issued under AmerisourceBergen's DLA Troop Support Medical prime indefinite delivery contract (SPE2DX), valued at $999,999,999.00 and extending through December 2026, which serves as a comprehensive global pharmaceutical support vehicle for military healthcare programs. AmerisourceBergen is one of the nation's largest pharmaceutical distributors and functions as a critical vendor for federal medical procurement across the Defense Health Agency, U.S. Coast Guard, and other government healthcare systems. The contract demonstrates the company's capability to fulfill diverse medical supply needs through open competition, with the DLA planning to establish next-generation pharmaceutical prime vendor contracts with multiple regional awards.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $11.3k | 10/17/25 |